Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.47 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427373 | 1.00 | SPHK1 (0.47) | SPHK1SPHK2POLBL3MBTL1S1PR1 | |
| SCHEMBL3429333 | 1.00 | SPHK1 (0.47) | SPHK1SPHK2POLBL3MBTL1S1PR1 | |
| SCHEMBL4026380 | 0.94 | SPHK1 (0.46) | SPHK1SPHK2POLBL3MBTL1S1PR1 | |
| SCHEMBL4295779 | 0.94 | SPHK1 (0.46) | SPHK1SPHK2POLBL3MBTL1S1PR1 | |
| SCHEMBL3426906 | 0.88 | POLB (0.48) | SPHK1SPHK2POLBL3MBTL1S1PR1 | |
| SCHEMBL3428908 | 0.88 | POLB (0.48) | SPHK1SPHK2POLBL3MBTL1S1PR1 | |
| SCHEMBL3428778 | 0.88 | POLB (0.48) | SPHK1SPHK2POLBL3MBTL1S1PR1 | |
| SCHEMBL3429334 | 0.84 | SPHK2 (0.49) | SPHK1SPHK2POLBL3MBTL1S1PR1 | |
| SCHEMBL3425937 | 0.84 | SPHK2 (0.49) | SPHK1SPHK2POLBL3MBTL1S1PR1 | |
| SCHEMBL3427378 | 0.84 | SPHK2 (0.49) | SPHK1SPHK2POLBL3MBTL1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-7402585-B2 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | AURKC, AURKA, AURKB | SPHK1 802/4885SPHK2 743/4885POLB 1003/4885 |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | AURKC, AURKA, AURKB | SPHK1 776/4885SPHK2 815/4885POLB 852/4885 |
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | SPHK1 2758/4885SPHK2 2879/4885POLB 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.